arrow
D

Daniel E. Spratt

case western reserve university
H指数:76
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Increasing cancer stemness drives prostate cancer progression, plasticity, therapy resistance and poor patient survival

增加癌症干性驱动前列腺癌进展、可塑性、治疗抵抗和患者不良生存

2026-10-270
OAAI
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression

EMETPRO:一项多中心、国际性回顾性分析,评估早期进展的转移性激素敏感性前列腺癌患者

2026-05-290
PRE
Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial

通过嵌入式分子诊断试验理解随机对照试验的普适性

2026-04-240
OA
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials

种族与接受阿帕鲁他胺治疗患者生存期的关联:两项III期试验的合并分析

Cancer
IF5.1
2026-01-010
PRE
Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes

ANPEP的下调与侵袭性前列腺癌及不良疾病特异性预后相关

2025-12-260
OAAI
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

2025-12-170
OAAI
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer

表征全人群基因组风险分布,以开发用于临床局部前列腺癌患者预后判断的新型临床-基因组风险系统

2025-12-090
OA
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment

空间多组学鉴定出侵袭性前列腺癌特征,突出了肿瘤微环境中促炎性趋化因子活性。

2025-11-190
OAAI
Prostate Cancer, Version 3.2026

前列腺癌,版本3.2026,NCCN肿瘤学临床实践指南

2025-11-012
PRE
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial

立体定向调强放疗在根治性前列腺切除术后的应用(SCIMITAR):一项II期临床试验的4年结果

2025-09-300
PRE
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

肿瘤转录组范围表达分类器预测晚期前列腺癌的治疗敏感性

Cell
IF42.5
2025-08-260
OAAI
Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with orteronel for men with high-risk prostate cancer (NRG/RTOG 1115)

剂量 escalated 放射治疗和标准雄激素剥夺治疗(ADT)与剂量 escalated 放射治疗和奥曲酮增强雄激素剥夺治疗的高危前列腺癌患者的III期试验(NRG/RTOG 1115)

2025-07-230
PRE
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer

放疗与手术为基础的治疗策略在高风险前列腺癌中的比较

2025-07-190
PRE